Group 1: New Stock Listings Performance - Four new stocks, including Impression Da Hong Pao, Huazhang Biotech, Mingji Hospital, and Nanhua Futures, debuted but all experienced a decline on their first trading day [1] Group 2: Huazhang Biotech - Huazhang Biotech opened at HKD 33.8, which is 11.5% lower than the IPO price of HKD 38.2, resulting in a loss of HKD 880 per lot of 200 shares [2] - The company focuses on wound healing therapies and is an unprofitable biotech firm specializing in developing protein drugs, particularly platelet-derived growth factor (PDGF) drugs [2] - The company did not attract cornerstone investors, with Huatai International and CITIC Securities serving as joint sponsors [3] Group 3: Mingji Hospital - Mingji Hospital opened at HKD 6.5, down 30.4% from the IPO price of HKD 9.34, leading to a loss of HKD 1,420 per lot of 500 shares [4] - The company operates as a large private profit-oriented hospital group in East China, primarily managing two tertiary hospitals in Nanjing and Suzhou, with a focus on orthopedics, cardiovascular, oncology, and reproductive medicine [4] - Cornerstone investors include He Rong Technology, He Fu (China), and Suzhou Zhanxing, collectively subscribing to 49.63% of the total offering [5] Group 4: Impression Da Hong Pao - Impression Da Hong Pao opened at HKD 3.26, which is 9.4% lower than the IPO price of HKD 3.6, resulting in a loss of HKD 340 per lot of 1,000 shares [6] - The company operates based on Wuyi Mountain tea culture, providing tourism performances and related services, with its core revenue source being the live performance "Impression Da Hong Pao," accounting for over 85% of its income [6] - The company was oversubscribed by over 3,400 times, with joint sponsors being Xingsheng International and Kaisen [6] Group 5: Nanhua Futures - Nanhua Futures opened at HKD 9.13, down 23.9% from the IPO price of HKD 12, leading to a loss of HKD 1,435 per lot of 500 shares [7] - The company is a futures brokerage listed on the A-share main board, primarily engaged in futures brokerage, investment consulting, asset management, and securities investment fund distribution, focusing on derivative business [7] - CITIC Securities is the sole sponsor for the company [7]

Core Viewpoint - Huazhang Biopharmaceutical-B (02396) has made its debut on the stock market with an initial share price of HKD 38.2, issuing 17.6488 million shares and raising approximately HKD 600 million in net proceeds. As of the report, the stock has dropped by 11.52% to HKD 33.8, with a trading volume of HKD 103 million [1]. Company Overview - Established in 2012, Huazhang Biopharmaceutical is a biopharmaceutical company headquartered in China, focusing on developing therapies, particularly protein drugs for indications with medical needs and market opportunities [1]. - The company's primary focus is on discovering, developing, and commercializing wound healing therapies, with a pipeline that includes ten candidate products, seven of which are PDGF candidates [1]. Product Pipeline - The two core products are Pro-101-1, aimed at treating burns, and Pro-101-2, intended for diabetic foot treatment, both of which are rhPDGF-BB drugs [1]. - According to a Frost & Sullivan report, as of the last feasible date, there are three PDGF drug pipelines in China, with no approved PDGF drugs available in the market [1]. - All PDGF pipelines are based on the PDGF-BB isoform, with two pipelines belonging to Huazhang Biopharmaceutical, which entered Phase II clinical trials for diabetic foot treatment in February 2022 and is expected to complete patient enrollment for Phase IIb clinical trials for treating second-degree and superficial burns by April 2025 [1].

每经AI快讯，12月22日，华芢生物-B（02396.HK）首挂上市，每股定价38.2港元，共发行1764.88万股 股份，每手200股，所得款项净额约6亿港元。截至发稿，华芢生物-B跌11.52%，报33.8港元，成交额 1.03亿港元。 ...

Core Viewpoint - Huazhang Biopharma-B (02396) has made its debut on the stock market with an initial share price of HKD 38.2, raising approximately HKD 600 million through the issuance of 17.6488 million shares, but the stock has seen a decline of 11.52% to HKD 33.8 at the time of reporting [1] Company Overview - Established in 2012, Huazhang Biopharma is a biopharmaceutical company based in China, focusing on the development of therapies, particularly protein drugs targeting medical needs and market opportunities [1] - The company's primary focus is on discovering, developing, and commercializing wound healing therapies, with a pipeline that includes ten candidate products, seven of which are PDGF candidates [1] Product Pipeline - The two core products in the pipeline are Pro-101-1 for treating burns and Pro-101-2 for treating diabetic foot, both of which are rhPDGF-BB drugs [1] - According to a Frost & Sullivan report, as of the last feasible date, there are three PDGF drug pipelines in China, with no PDGF drugs approved in the country [1] - All PDGF pipelines are based on the PDGF-BB isoform, with two pipelines belonging to Huazhang Biopharma, which entered Phase II clinical trials for diabetic foot treatment in February 2022 and is expected to complete patient enrollment for Phase IIb clinical trials for treating second-degree and superficial burns by April 2025 [1]

其中，香港公开发售获791.95倍认购，国际发售获6.05倍认购。 华芢生物-B(02396)公布配发结果，公司全球发售1764.88万股股份，香港公开发售占10%，国际发售占 90%。每股发售价38.2港元，净筹约6亿港元。每手200股，预期H股将于2025年12月22日(星期一)上午九 时正(香港时间)开始在联交所买卖。 ...

智通财经APP讯，华芢生物-B(02396)公布配发结果，公司全球发售1764.88万股股份，香港公开发售占 10%，国际发售占90%。每股发售价38.2港元，净筹约6亿港元。每手200股，预期H股将于2025年12月 22日(星期一)上午九时正(香港时间)开始在联交所买卖。 其中，香港公开发售获791.95倍认购，国际发售获6.05倍认购。 ...

假设全球发售于2025年12月22日(星期一)上午八时正或之前(香港时间)成为无条件，预期H股将于2025 年12月22日(星期一)上午九时正(香港时间)开始在联交所买卖。H股将以200股H股为一手买卖单位进行 交易，H股的股份代号为2396。 格隆汇12月19日丨华芢生物-B(02396.HK)公告，公司全球发售17,648,800股H股，每股H股38.20港元， 所得款项净额6亿港元。香港公开发售股份数目占全球发售股份数目10.00%，获认购791.95倍；国际发 售股份数目占全球发售股份90.00%，获认购倍6.05倍。 ...

香港交易及結算所有限公司、香港聯合交易所有限公司（「聯交所」）及香港中央結算有限公司 （「香港結算」）對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表 示，概不對因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任 何責任。 本公告不會直接或間接在或向美國（包括美國的領土及屬地、任何州及哥倫比亞特區）發佈、 刊發及派發。本公告並不構成或組成於美國或任何其他司法權區購買或認購證券的任何要約 或招攬的一部分。本公告所述證券並無亦將不會根據1933年美國證券法（經不時修訂）（「美國 證券法」）或美國任何州的證券法登記。證券不得於美國境內或向美國人士（定義見美國證券 法S規例（「S規例」））或代表美國人士或為其利益提呈發售、出售、質押或轉讓，惟獲豁免遵 守美國證券法登記規定或屬毋須遵守美國證券法登記規定的交易除外。發售股份可於美國境 外根據S規例以離岸交易方式向非美國人士提呈、出售或交付。 本公告僅供參考，並不構成收購、購買或認購證券的邀請或要約。本公告並非招股章程。潛 在投資者於決定是否投資於藉此提呈發售的H股前，應細閱華芢生物科技（青島）股份有限公 司（「本公司」）日期為20 ...

华芢生物-B(02396)将于12月22日(周一)在香港挂牌。截至收盘，利弗莫尔证券暗盘交易显示报价38.42港元，较招股价38.20港元上涨0.58%，每手200股， 不计手续费，每手赚44港元。 | 55.489 | 45.26% | | | | --- | --- | --- | --- | | | | 十档 | 成交明细 | | | | 38.660 | - - - - - - ) | | | | 38.640 | - - (- -) | | | | 38.620 | - -(- -) | | | | 38.600 | - -(- -) | | | | 38.580 | - -(- -) | | | | 38.560 | - - (- -) | | | | 38.540 | - - - - - - ) | | | | 38.520 | 200(1家) | | 38.200 | | 38.500 | 200(1家) | | | | 38.480 | 400(2家) | | | | 38.420 | 4000(1家) | | | | 38.400 | 200(1家) | | | | 38.380 | 10 ...

智通财经APP获悉，华芢生物-B(02396)将于12月22日(周一)在香港挂牌。截至收盘，利弗莫尔证券暗盘交易显示报价38.42港元，较招股价38.20港元上涨 0.58%，每手200股，不计手续费，每手赚44港元。 | 38.420 | | | | --- | --- | --- | | < +0.58% +0.220 换手 1.73% | 华花生物 - B HK 02396 暗盘 最低 34.400 | Q O 总市 31.90亿 | 38.240 - -(- -) 16:15 17:30 18:00 18:30 17:00 5分 1分 સ્ત્ર 日K 卖盘十档 买盘十档 94.65% 5.35% 立即买入 立即卖出 • 行情来源: 利弗莫尔证券 • | 55.489 | 45.26% | | | | --- | --- | --- | --- | | | | 十档 | 成交明细 | | | | 38.660 | - - - - - - ) | | | | 38.640 | - - (- -) | | | | 38.620 | - -(- -) | | | | 38.600 38.580 | - - ...